(Q44148970)

30 November 2017

title

Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function (English)

1 reference

30 November 2017

1 reference

1 reference

4

Jeffrey Lieberman

1 reference

30 November 2017

Gary Duncan

1

1 reference

30 November 2017

Seiya Miyamoto

2

1 reference

30 November 2017

Hongbin Gu

3

1 reference

30 November 2017

Beverly Koller

5

1 reference

30 November 2017

John Snouwaert

6

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

951

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

166-176

1 reference

Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Positron emission tomography studies of abnormal glucose metabolism in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Regional cerebral glucose metabolism in never-medicated patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

The glutamatergic dysfunction hypothesis for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Decreased anterior cingulate gyrus metabolic rate in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Recent advances in the phencyclidine model of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Brain imaging in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Effects of ketamine in normal and schizophrenic volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Provocative tests with psychostimulant drugs in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Mice with reduced NMDA receptor expression display behaviors related to schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Glutamate receptor dysfunction and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903156-6

10.1016/S0006-8993(02)03156-6

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference